| Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
| Dopaminergic drug used in parkinsonism adverse reaction |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Levodopa adverse reaction |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Benserazide + levodopa adverse reaction |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Apomorphine adverse reaction (disorder) |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Lysuride adverse reaction |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Pergolide adverse reaction |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Bromocriptine adverse reaction |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Decarboxylase inhibitor adverse reaction (disorder) |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Drug groups primarily affecting the central nervous system allergy |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Dopaminergic drug used in parkinsonism allergy |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Levodopa allergy |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Allergy to benserazide and levodopa |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Allergy to apomorphine |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Lysuride allergy |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Pergolide allergy |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Allergy to bromocriptine |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Decarboxylase inhibitor allergy |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Overdose of drug groups primarily affecting the central nervous system |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Overdose of dopaminergic drug used in parkinsonism |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Levodopa overdose (disorder) |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Accidental levodopa overdose |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Intentional levodopa overdose |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| surdose de lévodopa d'intention indéterminée |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Lysuride overdose |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Accidental lysuride overdose |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Intentional lysuride overdose (disorder) |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Lysuride overdose of undetermined intent |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Bromocriptine overdose |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Accidental bromocriptine overdose |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Intentional bromocriptine overdose |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| surdose de bromocriptine d'intention indéterminée |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Overdose of anticonvulsant drug |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Vigabatrin overdose (disorder) |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Accidental vigabatrin overdose (disorder) |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Intentional vigabatrin overdose |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| surdose de vigabatrine d'intention indéterminée |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Decarboxylase inhibitor overdose (disorder) |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Psychostimulant overdose |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Overdose of ecstasy |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Intentional overdose of ecstasy |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Overdose of ecstasy of undetermined intent |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Overdose of cocaine (disorder) |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Accidental overdose by cocaine |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Intentional overdose by cocaine |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Overdose of cocaine of undetermined intent |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Overdose of crack cocaine |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Accidental overdose by crack cocaine |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Intentional overdose by crack cocaine |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Overdose of crack cocaine of undetermined intent |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Caffeine overdose |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Accidental caffeine overdose |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Intentional caffeine overdose |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| surdose de caféine d'intention indéterminée |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Sedative, hypnotic AND/OR anxiolytic-induced persisting amnestic disorder |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Sedative, hypnotic AND/OR anxiolytic-related disorder (disorder) |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Magnesium sulfate powder |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Magnesium sulfate 4g/10mL mixture |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Magnesium sulfate BP crystals |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Drugs used in nausea and vertigo |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Drugs for the control of epilepsy |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Vigabatrin-containing product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Vigabatrin 500 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely vigabatrin 500 milligram/1 sachet powder for conventional release oral solution (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Drugs used in status epilepticus |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Levodopa 500 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Levodopa with benserazide |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Benserazide 12.5 mg and levodopa 50 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Benserazide 25 mg and levodopa 100 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely benserazide 50 milligram and levodopa 200 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Co-beneldopa 12.5mg/50mg dispersible tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Co-beneldopa 25mg/100mg m/r capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Co-beneldopa 25mg/100mg dispersible tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Bromocriptine [parkinsons] |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Parlodel starter |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely lisuride 200 microgram/1 each conventional release oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely pergolide 50 microgram/1 each conventional release oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely pergolide 250 microgram/1 each conventional release oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely pergolide 1 milligram/1 each conventional release oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Pergolide 50micrograms+250micrograms tablet starter pack (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Apomorphine hydrochloride 20mg/2mL injection (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Apomorphine hydrochloride 50mg/5mL injection (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| chlorhydrate d'apomorphine 30 mg/3 mL, stylo-injecteur prérempli |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ropinirole (as ropinirole hydrochloride) 250 microgram oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ropinirole (as ropinirole hydrochloride) 1 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ropinirole (as ropinirole hydrochloride) 2 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely ropinirole (as ropinirole hydrochloride) 5 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Cabergoline [parkinsons] |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Cabergoline 1 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Cabergoline 2mg tablet (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Cabergoline 4 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely pramipexole dihydrochloride 88 microgram/1 each conventional release oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely pramipexole dihydrochloride 180 microgram/1 each conventional release oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely pramipexole dihydrochloride 700 microgram/1 each conventional release oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Biperiden hydrochloride 2 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Cerebral vessel spasmolytic |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Drugs used in substance dependence |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Drugs used for the treatment of motor neurone disease |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Centrally acting acetylcholinesterase inhibitor-containing product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Donepezil hydrochloride 5 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely donepezil hydrochloride 10 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing rivastigmine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
FHIR
© HL7.org
|
Server Home |
FHIR Server FHIR Server 3.7.4-SNAPSHOT
|
FHIR Version n/a
User: [n/a]